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Abstract
Human T lymphotropic virus type 1 (HTLV-1) is the causal agent of myelopathy/tropical spastic paraparesis (HAM/TSP), a 
disease mediated by the immune response. HTLV-1 induces a spontaneous proliferation and production of pro-inflammatory 
cytokines by T cells, and increasing interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α) levels are potentially involved 
in tissue damage in diseases related to HTLV-1. This exaggerated immune response is also due to an inability of the natural 
regulatory mechanisms to down-modulate the immune response in this group of patients. TNF-α inhibitors reduce inflamma-
tion and have been shown to improve chronic inflammatory diseases in clinical trials. The aim of this study was to evaluate the 
ability of pentoxifylline, forskolin, rolipram, and thalidomide to decrease in vitro production of TNF-α and IFN-γ in cells of HTLV-
1-infected subjects. Participants of the study included 19 patients with HAM/TSP (mean age, 53 ± 11; male:female ratio, 1:1) 
and 18 HTLV-1 carriers (mean age, 47 ± 11; male:female ratio, 1:2.6). Cytokines were determined by ELISA in supernatants 
of mononuclear cell cultures. Pentoxifylline inhibited TNF-α and IFN-γ synthesis with the minimum dose used (50 µM). The 
results with forskolin were similar to those observed with pentoxifylline. The doses of rolipram used were 0.01-1 µM and the 
best inhibition of TNF-α production was achieved with 1 µM and for IFN-γ production it was 0.01 µM. The minimum dose of 
thalidomide used (1 µM) inhibited TNF-α production but thalidomide did not inhibit IFN-γ production even when the maximum 
dose (50 µM) was used. All drugs had an in vitro inhibitory effect on TNF-α production and, with the exception of thalidomide, 
all of them also decreased IFN-γ production.
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Human lymphotropic virus type 1 (HTLV-1) infection 
is endemic in Brazil (1) and the city of Salvador has the 
highest prevalence among blood donors (1.35%) and in 
the population (1.76%) (2,3). HTLV-1 is the causal agent 
of adult T-cell leukemia-lymphoma (ATL), and of a chronic 
inflammatory disease of the central nervous system (HTLV-1 
associated myelopathy/tropical spastic paraparesis, HAM/
TSP) (4). HTLV-1 infection induces T-cell activation and in 
vitro spontaneous lymphocyte proliferation leading to the 
production of high levels of interferon-γ (IFN-γ) and tumor 
necrosis factor-α (TNF-α) in non-stimulated peripheral blood 
mononuclear cells (PBMC) (5,6). HAM/TSP is characterized 
by progressive spastic paraparesis and occurs in less than 
5% of HTLV-1-infected patients (7). High proviral load (8,9) 
and increased expression of the pro-inflammatory cytokines 
TNF-α and IFN-γ in PBMC as well as interleukin-1 (IL-1) 
and IL-6 in the cerebrospinal fluid (CSF) are associated 
with this disease (4,10). Although these cytokines are more 
pronounced in HAM/TSP patients, evidence of enhanced 
T-cell activation is also detected in HTLV-1 carriers (11). 
Moreover, a large proportion of HTLV-I carriers, although 
they do not fulfill the criteria for HAM/TSP, have neurologi-
 Effect of TNF-α production inhibitors in HTLV-1 infection 1135
www.bjournal.com.br Braz J Med Biol Res 44(11) 2011
cal symptoms such as erectile dysfunction and neurogenic 
bladder, features that may precede the development of 
HAM/TSP (12,13). 
Due to the role of pro-inflammatory mediators in the 
pathogenesis of tissue damage associated with HTLV-1 in-
fections, immunomodulatory agents are natural candidates 
to be used as adjuvant therapy in patients with HAM/TSP and 
in individuals who are at higher risk to develop myelopathy. 
Neutralization of TNF-α has been the most successful form 
of immunotherapy among the cytokine antagonists used in 
clinical practice (14-17). Inhibition of TNF-α synthesis can 
be achieved by several means: inhibition of transcription, 
decrease of mRNA half-life, and inhibition of translation 
(18). Although some substances act on more than one level, 
there are at least preferential modes of action. Pentoxifylline 
increases cAMP, blocks the transcription of TNF-α mRNA 
from macrophages (14) and down-regulates in vivo and in 
vitro the expression of intracellular adhesion molecule-1 
(ICAM-1) in monocytes (19). Rolipram acts by blocking the 
transcription of TNF-α mRNA from macrophages; however, 
compared to pentoxifylline, it is more potent in suppressing 
TNF-α production from PBMC of patients with HAM/TSP 
(20). Thalidomide decreases the half-life of TNF-α mRNA 
(14,15,21). The role of TNF-α in the inflammatory process 
has been documented in several inflammatory and infectious 
diseases such as multiple sclerosis, inflammatory bowel 
diseases, rheumatoid arthritis, and mucosal leishmaniasis 
(14,16,17). The purpose of the present study was to evaluate 
the ability of TNF-α production inhibitors to decrease the 
in vitro production of pro-inflammatory cytokines such as 
IFN-γ and TNF-α. The overall data showed that all drugs 
had an inhibitory effect on TNF-α production and, with the 
exception of thalidomide, all of them also decreased IFN-γ 
production. 
Material and Methods
Study design and patient selection
This was an experimental in vitro study evaluating the 
effect of four TNF-α inhibitors, i.e., pentoxifylline, forskolin, 
rolipram, and thalidomide, in PBMC of individuals infected 
with HTLV-1. Samples were taken under informed consent, 
and the study was conducted with the approval of the Eth-
ics Committee of Hospital Universitário Professor Edgard 
Santos. The study subjects consisted of 37 patients who at-
tended the HTLV-1 clinic of Hospital Universitário Professor 
Edgard Santos, Universidade Federal da Bahia, Brazil. All 
patients were evaluated by a neurologist. Motor and other 
neurological dysfunctions were measured with two scales: 
Expanded Disability Status Scale (EDSS) (22) and Osame’s 
Motor Disability Score (OMDS). Exclusion criteria were 
positive serology for HIV-1 and -2, syphilis, and hepatitis 
virus B or C infection. Seven HTLV-1-negative individuals 
participated as controls. Nineteen (53 ± 11 years old) of 
the 37 HTLV-1-positive subjects had HAM/TSP defined by 
neurological abnormalities (OMDS ≥1 EDSS ≥2) and the 
presence of anti-HTLV-1 antibody in CSF. The other 18 
individuals (47 ± 11 years old) were HTLV-1 carriers and 
had OMDS = 0 and EDSS ≤2. The diagnosis of HTLV-1 
infection was based on a positive serology by ELISA (Murex 
HTLV-I + II, England), confirmed by Western blot analysis 
(Genelabs HTLV 2.3-2.4, Singapore). 
PBMC cultures and in vitro assays of drug effects
PBMC from HTLV-1-infected individuals and controls 
were isolated from heparinized blood by density gradient 
centrifugation with Ficoll-Hypaque as described (6). Briefly, 
PBMC were washed with saline and 3 x 106 cells/mL per 
well were cultured on 24-well flat-bottom plates (Falcon, 
Becton Dickinson, USA), in RPMI 1640 (Life Technologies 
Gibco BRL, USA), supplemented with 10% human AB 
serum (Sigma, USA), glutamine, HEPES, and antibiot-
ics. The cultures were kept without a stimulus for 72 h at 
37°C, 5% CO2 in the absence or presence of the TNF-α 
inhibitors. TNF-α and IFN-γ levels were measured in cell 
supernatants by the ELISA sandwich technique accord-
ing to manufacturer instructions (PharMingen, USA). The 
activity of TNF-α inhibitors and cell viability were tested by 
evaluating the best dose able to inhibit TNF-α and IFN-γ 
while maintaining cell viability. Dose-response curves were 
constructed using non-stimulated PBMC from HAM/TSP 
patients and PBMC from healthy controls stimulated with 
phytohemagglutinin (PHA) at a final dilution of 1:10. The 
concentrations of the drugs tested were: 1, 10, 50, and 200 
μM for pentoxifylline, forskolin, and thalidomide, and 0.01, 
0.1, 1, 10, 100 μM for rolipram. Cell viability was measured 
by counting the number of live cells stained with Trypan blue 
after 72-h incubation with the drugs tested. The results are 
reported as pg/mL by interpolation in a standard curve with 
the recombinant cytokines.
Semi-quantitative reverse transcriptase-polymerase 
chain reaction (RT-PCR) to detect IFN-γ
Total RNA was isolated from PBMC of 4 HAM/TSP 
and 8 HTLV-1 carriers with and without pentoxifylline (50 
µM). The RNA was extracted from PBMC using Trizol LS 
reagent (Invitrogen, USA). cDNA was synthesized using 3 
mg total RNA and reverse-transcribed by M-MLV reverse 
transcriptase. PCR was then performed in a final volume 
of 50 µL containing 2.0 mM MgCl2, 0.2 mM deoxyribo-
nucleoside triphosphate (dNTP) mix (dATP, dCTP, dTTP, 
dGTP), 10X PCR buffer, 2.5 U Taq DNA polymerase 
recombinant (Invitrogen), and specific primers at 25-50 
pmol using a Veriti Thermal Cycler (Applied Biosystems, 
USA). The human primer sequences were: HPRT for-
ward: GCGTCGTGATTAGTGATGATGAAC and HPRT 
reverse: GGATTATACTGCCTGACCAAGG; IFN-γ forward: 
CAGCTCTGCATCGTTTTGGGTTCT and IFN-γ reverse: 
TGCTCTTCGACCTCGAAACAGCAT. The PCR profiles 
used were: 30 cycles of 1 min at 95°C for denaturation, 1 min 
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at 60°C for annealing and extension for 1 
min 30 s at 72°C, plus a final extension 
step of 10 min at 72°C. The PCR amplifi-
cation products were visualized on 1.3% 
agarose gel stained with 0.2% ethidium 
bromide (Sigma). Band intensity was 
calculated using the Vision Works LS 
image acquisition system version 6.5.2 
(UVP, UK). Results are reported as 
relative units (RU) corrected for HPRT 
expression.
Statistical analysis
The nonparametric Mann-Whitney 
U-test was used to compare data 
between patients with HAM/TSP and 
HTLV-1 carriers. The nonparametric paired Wilcoxon 
signed rank test was used to compare the cytokine levels 
in PBMC culture supernatants without and with the drugs 
tested. These tests were performed using the Instat pro-
gram (USA), and P values <0.05 were considered to be of 
statistical significance.
Results
Study subjects and IFN-γ and TNF-α levels
The degree of neurological dysfunction and the concen-
trations of TNF-α and IFN-γ in 19 patients with HAM/TSP 
and 18 HTLV-1 carriers are shown is Table 1. There was 
no difference in age between the two groups. As expected, 
EDSS and OMDS scores were higher in patients with HAM/
TSP than in HTLV-1 carriers. There was wide variability in 
the levels of both cytokines. The median IFN-γ level was 291 
pg/mL, with values ranging from 0 to 1,877 pg/mL, in HAM/
TSP patients, and 11 pg/mL, with values ranging from 0 to 
1,950 pg/mL, in HTLV-1 carriers (P = 0.017). The median 
level of TNF-α was 148 pg/mL in HAM/TSP patients, ranging 
from 0 to 1,334 pg/mL, and 5 pg/mL in HTLV-1 carriers, with 
values ranging from 0 to 926 pg/mL (P = 0.013). 
Effect of TNF-α inhibitors
The effect of TNF-α inhibitors was determined in all 
infected subjects, independent of group, who had spontane-
ous TNF-α and IFN-γ production >50 pg/mL. Since IFN-γ 
levels were higher than TNF-α levels in HTLV-1 infection, 
there were more patients in the experiments evaluating 
IFN-γ inhibition (N = 16) than TNF-α inhibition (N = 9). For 
each drug in culture the minimum and maximum doses able 
to suppress TNF-α and IFN-γ in PHA-stimulated cultures and 
to maintain cell viability were used. Since rolipram was the 
least used of the three drugs tested, three concentrations of 
rolipram were used. Percent TNF-α and IFN-γ inhibition by 
pentoxifylline is shown in Table 1 and the concentrations of 
these cytokines observed in cultures without and with TNF-α 
inhibitors are shown in Figures 1, 2, and 3. The percentage 
Figure 1. Effect of pentoxifylline on TNF-α and IFN-γ levels. 
PBMC from HTLV-1-infected individuals (N = 9 and N = 5) were 
exposed to 50 and 200 µM pentoxifylline and the levels of TNF-α 
(A) and IFN-γ (B) were measured by ELISA. Cell viability was 
tested by counting the live and dead cells stained with Trypan 
blue after incubation with the drugs tested. TNF-α = tumor necro-
sis factor-α; IFN-γ = interferon-γ; PBMC = peripheral blood mono-
nuclear cells; HTLV-1 = human T lymphotropic virus type 1.
Table 1. Demographic, clinical and immunological characteristics of HTLV-I carriers 
and HAM/TSP patients.
Clinical and immunological features HAM/TSP (N = 19) HTLV-I carriers (N = 18)
Age (years) 53 ± 11 (38-75) 47 ± 11 (27-66)
EDSS score 4.5 ± 1.8 (2.5-8.0) 1.5 ± 0.2 (1.0-1.5)*
OMDS score 4 ± 1.9 (1-10) 0
Spontaneous IFN-γ (pg/mL) 513 ± 650 (0-1,877) 197 ± 470 (0-1,950)*
Spontaneous TNF-α (pg/mL) 332 ± 423 (0-1,334) 131 ± 277 (0-926)*
Data are reported as means ± SD (range in parentheses). HAM/TSP = myelopathy/
tropical spastic paraparesis; HTLV-1 = human T lymphotropic virus type 1; EDSS = 
Expanded Disability Status Scale; OMDS = Osame’s Motor Disability Score. *P < 0.05 
compared to HAM/TSP (Mann-Whitney U-test). 
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of TNF-α inhibitor represents the data observed with the total 
number of individuals including HTLV-1 carriers and patients 
with HAM/TSP because the inhibition observed in these two 
groups was similar. For instance, the mean TNF-α inhibition 
with 50 µM pentoxifylline in cells from the total group of 9 
HTLV-1-positive subjects was 71 ± 26%, being 72 ± 28% in 
6 HAM/TSP patients and 70 ± 30% in 3 HTLV-1 carriers (P = 
0.92). At a concentration of 200 µM, the inhibition of TNF-α 
observed in cell cultures of HTLV-1-positive subjects was 84 
± 25-86 ± 27% in the HAM/TSP group and 82 ± 16% in the 
HTLV-1 carriers (P = 0.85). Pentoxifylline also decreases 
IFN-γ synthesis. The inhibition of IFN-γ production was 46 
± 24% with 50 µM pentoxifylline and 65 ± 29% with 200 
µM. As shown in Figure 1A and B, cell viability at the high-
est concentration of the drug was 80%. The results with 
forskolin were similar to those observed with pentoxifylline. 
The inhibition of TNF-α production was 77 ± 25% with 50 
µM forskolin and 73 ± 29% with 200 µM. The inhibition of 
IFN-γ synthesis was 61 ± 22 and 77 ± 25%, respectively. 
The cell viability at the highest concentration of the drug 
was 79%. The doses of rolipram used were 0.01, 0.1, and 
1 µM. The best inhibition of TNF-α production was achieved 
with 1 µM, which caused 80 ± 22% inhibition (Figure 2A). 
The minimum dose of rolipram (0.01 µM) inhibited IFN-γ 
production by 47 ± 20% while the maximum dose (1.0 µM) 
inhibited it by 50 ± 24% (Figure 2B). The cell viability with 1 
µM rolipram was 91%. The minimum dose of thalidomide 
used (1 µM) was able to inhibit TNF-α production by 65 ± 
22% (Figure 3). Moreover, IFN-γ levels after the addition of 
thalidomide were assayed only in five expe riments because 
thalidomide showed no inhibitory effect on IFN-γ (less than 
50% inhibition) when the maximum dose (50 µM) was used. 
These results show that pentoxifylline, forskolin and rolipram 
were able to suppress in vitro TNF-α and IFN-γ production. 
It was also observed that thalidomide was efficient only in 
suppressing TNF-α synthesis. 
Detection of IFN-γ mRNA by RT-PCR
Since the ability of these drugs to decrease IFN-γ pro-
duction represents new information, we evaluated whether 
pentoxifylline inhibited TNF-α RNA at the molecular level.
PBMC from HTLV-1-infected patients were cultured 
with and without 50 μM pentoxifylline. After 72 h of culture 
the cells were harvested and IFN-γ mRNA expression was 
analyzed by RT-PCR. IFN-γ mRNA expression was detected 
in all cultures (with and without 50 μM pentoxifylline) and 
no difference was observed between the HTLV-1-infected 
groups (data not shown). 
Figure 2. Effect of rolipram on TNF-α and IFN-γ levels. PBMC 
from HTLV-1-infected individuals (N = 8 and N = 10) were ex-
posed to 0.01 µM, 0.1 µM, and 1.0 µM rolipram and the levels of 
TNF-α (A) and IFN-γ (B) were measured by ELISA. Cell viability 
was tested by counting the live and dead cells stained with Try-
pan blue after incubation with the drugs tested. For abbrevia-
tions, see legend to Figure 1.
Figure 3. Effect of 1 and 50 µM thalidomide on TNF-α levels of 
PBMC from HTLV-1-infected individuals (N = 8). The levels of 
TNF-α were measured by ELISA. Cell viability was tested by 
counting the live and dead cells stained with Trypan blue after 
incubation with the drugs tested. For abbreviations, see legend 
to Figure 1.
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Discussion
HAM/TSP is a chronic immune-mediated neurologic 
disease characterized by leg weakness and spastic parapa-
resis that leads to physical disability (23,24). TNF-α plays an 
important role in the pathogenesis of chronic inflammatory 
diseases (18). In HAM/TSP, IFN-γ and TNF-α may contribute 
to tissue damage by recruiting inflammatory cells and induc-
ing apoptosis. Moreover, these cytokines are also increased 
in serum and CSF and also stimulate nitric oxide (NO) and 
metalloproteinase synthesis (18). We show here that several 
drugs known to decrease TNF-α synthesis inhibit not only 
TNF-α but also IFN-γ production in vitro by PBMC of both 
HTLV-1 carriers and HAM/TSP patients.
In the present study, we compared the action of TNF-α 
inhibitors on spontaneous TNF-α and IFN-γ production 
by PBMC of HTLV-1-infected individuals to evaluate the 
effective dose needed to suppress the production of these 
cytokines and to maintain cell viability. These in vitro tests 
are important due to the wide variability in the activation 
state or deregulation of the immune system during HTLV-1 
infection, which may influence the effects of drugs, including 
enhancement of cellular toxicity. Our in vitro results show 
that rolipram suppresses both TNF-α and IFN-γ production 
by cell cultures from HTLV-1-infected subjects even at very 
low concentrations.
Pentoxifylline has been extensively studied in terms 
of TNF-suppressing activity (25). Pentoxifylline has been 
effective in the treatment of erythema nodosum in leprosy 
(26,27) and, in combination with antimony therapy, it ac-
celerates the healing time of cutaneous and mucosal leish-
maniasis and the cure of patients refractory to antimony 
therapy (16,28-30). Our results show that pentoxifylline 
had a good suppressor effect on the spontaneous produc-
tion of TNF-α, preserving cell viability. Additionally, it also 
decreased IFN-γ production to a lesser extent. Forskolin 
had an effect similar to that of pentoxifylline; however, it 
was more efficient in inhibiting IFN-γ than pentoxifylline. 
Thalidomide analogues have been considered to have a 
high therapeutic potential for TNF-α inhibition by increasing 
the degradation of TNF-α mRNA in macrophages (15). Our 
results showed that thalidomide inhibited TNF-α produc-
tion by PBMC at a low dose (1 μM). However, it did not 
inhibit IFN-γ production. The specificity of thalidomide in 
inhibiting only TNF-α, preserving the production of IFN-γ, 
can be important in situations where it is necessary to pre-
serve the effector functions of this cytokine such as tumor 
cytotoxicity and antiviral activities, avoiding the induction 
of immunosuppression and predisposing to infections by 
intracellular agents and tumor development. Although IFN-γ 
production in HTLV-1 infection can be decreased by these 
drugs, the molecular mechanisms leading to the suppres-
sion of this cytokine are still not fully understood. Here we 
showed that IFN-γ mRNA expression was not altered by 
pentoxifylline, indicating that in such case the inhibition is 
post-transcriptional, either regarding protein synthesis or 
protein secretion. 
The drugs tested in the present study showed a high 
inhibitory effect on TNF-α production in vitro and, to a lesser 
extent, on IFN-γ production by PBMC from HTLV-1-infected 
patients. IFN-γ and TNF-α levels are very high in HTLV-1 
infection and a possible role of these cytokines in both 
defense mechanisms but also in pathology associated with 
infection have been considered. IFN-γ activates cytotoxic 
T cells and stimulates TNF-α secretion and could induce 
neuronal destruction mediated by HTLV-1-specific cytotoxic 
CD8 T cells and the production of mediators such as NO 
and metalloproteinases. 
There is no effective therapy for HTLV-1. Anti-retroviral 
agents used for HIV associated with other drugs have 
improved the prognosis of ATL, but little effect has been 
shown on HAM/TSP (31). The pathogenesis of HAM/TSP 
is dependent on an exacerbated immunological response 
induced by the Tax gene of HTLV-1. However, although a 
large proportion of HTLV-1 carriers produce high levels of 
IFN-γ and TNF-α, they do not develop the disease (6,32). 
We have observed that, in contrast to cells from patients 
with HAM/TSP, PBMC from HTLV-1 carriers can be down-
modulated in vitro by regulatory cytokines such as IL-10 and 
TGF-β and neutralizing antibodies against IL-2 and IL-15 
(33). Other investigators have also shown a decrease in 
the frequency of regulatory T cells in patients with HAM/
TSP (34). These observations suggest that drugs having 
as target the inhibition of IFN-γ and TNF-α production are 
potential agents to be used in HAM/TSP. 
Anti-TNF-α therapy has been effective in other chronic 
disorders associated with high TNF-α levels such as 
rheumatoid arthritis, Crohn’s disease, multiple sclerosis, 
leprosy, and mucosal leishmaniasis (16,17,25,35,36). In 
HAM/TSP, open studies have also shown a beneficial effect 
of pentoxifylline (37,38). 
Pentoxifylline, rolipram, foskolin, and thalidomide in-
hibited TNF-α production in vitro in patients infected with 
HTLV-1. As down-modulation of the inflammatory response 
is desirable to prevent neurological damage in HTLV-1 
infection, this study gives support to the use of this type 
of drug alone or in combination with antiretroviral therapy 
in the treatment of HTLV-1-infected subjects at high risk to 
develop HAM/TSP.
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